Reduced postprandial GLP-1 responses in women with gestational diabetes mellitus

Diabetes, Obesity and Metabolism

Volumn 15, Issue 8, 2013, Pages 713-720

  Bonde, L ^a   Vilsboll T ^a   Nielsen, T ^a   Bagger, J I ^a   Svare, J A ^a   Holst, J J ^b   Larsen, S ^a   Knop, F K ^a,b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

GIP; GLP 1; Insulin resistance; Insulin secretion

Indexed keywords

C PEPTIDE; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; INCRETIN; INSULIN;

ADULT; AGE; AREA UNDER THE CURVE; ARTICLE; BODY MASS; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELIVERY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HUMAN; ORAL GLUCOSE TOLERANCE TEST; PREGNANCY DIABETES MELLITUS; TEST MEAL; THIRD TRIMESTER PREGNANCY;

EID: 84879799737     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12082     Document Type: Article

References (33)

1. Holst JJ. On the physiology of GIP and GLP-1. Horm Metab Res 2004; 36(11-12): 747-754.
2. Nauck M, Stockmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986; 29: 46-52.
3. Calanna S, Gluud LL, Holst JJ, Vilsbøll T, Knop FK. Secretion of Glucagon-Like Peptide-1 in Patients With Type 2 Diabetes Mellitus - Systematic Review and Meta-Analysis of Clinical Studies. Diabetes 2012; 61(S1): A482.Abstract.
4. Toft-Nielsen MB, Damholt MB, Madsbad S et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 2001; 86: 3717-3723.
5. Vaag AA, Holst JJ, Vølund A, Beck-Nielsen HB. Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM)-evidence for decreased glucagon-like peptide 1 secretion during oral glucose ingestion in NIDDM twins. Eur J Endocrinol 1996; 135: 425-432.
6. Nyholm B, Walker M, Gravholt CH et al. Twenty-four-hour insulin secretion rates, circulating concentrations of fuel substrates and gut incretin hormones in healthy offspring of Type II (non-insulin-dependent) diabetic parents: evidence of several aberrations. Diabetologia 1999; 42: 1314-1323.
7. Højberg PV, Vilsbøll T, Zander M et al. Four weeks of near-normalization of blood glucose has no effect on postprandial GLP-1 and GIP secretion, but augments pancreatic B-cell responsiveness to a meal in patients with Type 2 diabetes. Diabet Med 2008; 25: 1268-1275.
8. Rask E, Olsson T, Soderberg S et al. Impaired incretin response after a mixed meal is associated with insulin resistance in nondiabetic men. Diabetes Care 2001; 24: 1640-1645.
9. Chia CW, Carlson OD, Kim W et al. Exogenous glucose-dependent insulinotropic polypeptide worsens post prandial hyperglycemia in type 2 diabetes. Diabetes 2009; 58: 1342-1349.
10. Irwin N, Flatt PR. Evidence for beneficial effects of compromised gastric inhibitory polypeptide action in obesity-related diabetes and possible therapeutic implications. Diabetologia 2009; 52: 1724-1731.
11. Knop FK. Resolution of type 2 diabetes following gastric bypass surgery: involvement of gut-derived glucagon and glucagonotropic signalling? Diabetologia 2009; 52: 2270-2276.
12. Jones IR, Owens DR, Luzio S, Williams S, Hayes TM. The glucose dependent insulinotropic polypeptide response to oral glucose and mixed meals is increased in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1989; 32: 668-677.
13. Miyawaki K, Yamada Y, Ban N et al. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med 2002; 8: 738-742.
14. Clapp JF. Effects of Diet and Exercise on Insulin Resistance during Pregnancy. Metab Syndr Relat Disord 2006; 4: 84-90.
15. Bentley-Lewis R, Levkoff S, Stuebe A, Seely EW. Gestational diabetes mellitus: postpartum opportunities for the diagnosis and prevention of type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab 2008; 4: 552-558.
16. Ørskov C, Rabenhøj L, Wettergren A, Kofod H, Holst JJ. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide-1 in humans. Diabetes 1994; 43: 535-539.
17. Deacon CF, Nauck MA, Meier J, Hucking K, Holst JJ. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J Clin Endocrinol Metab 2000; 85: 3575-3581.
18. Bablok W, Passing H, Bender R, Schneider B. A general regression procedure for method transformation. Application of linear regression procedures for method comparison studies in clinical chemistry, Part III. J Clin Chem Clin Biochem 1988; 26: 783-790.
19. Ørskov C, Jeppesen J, Madsbad S, Holst JJ. Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine. J Clin Invest 1991; 87: 415-423.
20. Instructions for use. VITROS Chemistry Products ACET Slides. 13-9-2004: Patent
21. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
22. Medhus AW, Lofthus CM, Bredesen J, Husebye E. Gastric emptying: the validity of the paracetamol absorption test adjusted for individual pharmacokinetics. Neurogastroenterol Motil 2001; 13: 179-185.
23. Holst JJ, Knop FK, Vilsbøll T, Krarup T, Madsbad S. Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes. Diabetes Care 2011; 34(Suppl 2): S251-S257.
24. Nauck MA, Vardarli I, Deacon CF, Holst JJ, Meier JJ. Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? Diabetologia 2011; 54: 10-18.
25. Creutzfeldt W, Ebert R, Willms B, Frerichs H, Brown JC. Gastric inhibitory polypeptide (GIP) and insulin in obesity: increased response to stimulation and defective feedback control of serum levels. Diabetologia 1978; 14: 15-24.
26. Knop FK, Vilsbøll T, Larsen S et al. Increased postprandial responses of GLP-1 and GIP in patients with chronic pancreatitis and steatorrhea following pancreatic enzyme substitution. Am J Physiol Endocrinol Metab 2007; 292: E324-E330.
27. Cypryk K, Vilsbøll T, Nadel I, Smyczynska J, Holst JJ, Lewinski A. Normal secretion of the incretin hormones glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 during gestational diabetes mellitus. Gynecol Endocrinol 2007; 23: 58-62.
28. Lencioni C, Resi V, Romero F, Lupi R, Volpe L, Bertolotto A et al. Glucagons-like peptide-1 (GLP-1) secretion in women with gestational diabetes mellitus during and after pregnancy. J Endocrinol Invest 2011.
29. Horowitz M, Collins PJ, Cook DJ, Harding PE, Shearman DJ. Abnormalities of gastric emptying in obese patients. Int J Obes 1983; 7: 415-421.
30. Vollmer K, Gardiwal H, Menge BA et al. Hyperglycemia acutely lowers the postprandial excursions of glucagon-like Peptide-1 and gastric inhibitory polypeptide in humans. J Clin Endocrinol Metab 2009; 94: 1379-1385.
31. Meier JJ, Gallwitz B, Askenas M et al. Secretion of incretin hormones and the insulinotropic effect of gastric inhibitory polypeptide in women with a history of gestational diabetes. Diabetologia 2005; 48: 1872-1881.
32. Forbes S, Moonan M, Robinson S et al. Impaired circulating glucagon-like peptide-1 response to oral glucose in women with previous gestational diabetes. Clin Endocrinol (Oxf) 2005; 62: 51-55.
33. Yu SH, Cho B, Lee Y et al. Insulin secretion and incretin hormone concentration in women with previous gestational diabetes mellitus. Diabetes Metab J 2011; 35: 58-64.